for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ProQR Therapeutics NV

PRQR.OQ

Latest Trade

6.45USD

Change

-0.34(-5.01%)

Volume

65,489

Today's Range

6.28

 - 

6.89

52 Week Range

5.50

 - 

24.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.79
Open
6.86
Volume
65,489
3M AVG Volume
3.86
Today's High
6.89
Today's Low
6.28
52 Week High
24.00
52 Week Low
5.50
Shares Out (MIL)
48.00
Market Cap (MIL)
309.62
Forward P/E
-4.04
Dividend (Yield %)
--

Next Event

Q3 2019 ProQR Therapeutics NV Earnings Release

Latest Developments

More

ProQR Announces Proposed Underwritten Public Offering Of Ordinary Shares

ProQR Announces Positive Top-Line Results From Phase 1/2 Study Of Sepofarsen In LCA10 Patients

Proqr Receives Fast Track Designation From FDA For Qr-1123

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ProQR Therapeutics NV

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).

Industry

Biotechnology & Drugs

Contact Info

Zernikedreef 9

+31.854.894932

https://www.proqr.com/

Executive Leadership

Daniel Anton De Boer

Chief Executive Officer, Chairman of the Management Team

Dinko Valerio

Independent Chairman of the Supervisory Board

Smital Shah

Chief Business and Financial Officer, Member of the Management Team

Tiffany Burt

Vice President, Head - Commercial

Aniz Girach

Chief Medical Officer

Key Stats

1.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-1.769

2017

-1.617

2018

-1.090

2019(E)

-1.436
Price To Earnings (TTM)
--
Price To Sales (TTM)
52.60
Price To Book (MRQ)
3.53
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
14.92
LT Debt To Equity (MRQ)
14.66
Return on Investment (TTM)
-81.35
Return on Equity (TTM)
-70.34

Latest News

Latest News

ProQR soars as childhood blindness drug succeeds in early trial

Shares of ProQR Therapeutics NV surged 70 percent in premarket trading on Tuesday after an interim analysis of an early-stage trial showed that its experimental treatment for a rare form of childhood blindness improved vision.

ProQR drug for rare childhood blindness succeeds in early trial

Dutch drug developer ProQR Therapeutics NV said on Tuesday its interim analysis showed that an early-stage trial of an experimental treatment for a rare form of childhood blindness was successful in improving vision.

BRIEF-ProQR Announces Q1 Loss Per Share Eur 0.34

* AT MARCH 31, 2018, PROQR HELD CASH AND CASH EQUIVALENTS OF €38.0 MILLION, COMPARED TO €48.1 MILLION AT DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

BRIEF-ProQR Provides Enrollment Update On QR-110 Clinical Trial

* PROQR PROVIDES ENROLLMENT UPDATE ON QR-110 CLINICAL TRIAL AND HIGHLIGHTS OPHTHALMOLOGY PRESENTATIONS AT ARVO

BRIEF-Proqr Q4 Loss Per Share ‍Eur 0.39

* PROQR ANNOUNCES RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017 AND PROVIDES BUSINESS UPDATE

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

BRIEF-ProQR Receives Orphan Drug Designation From EMA For Drug Candidate Qr-313 For Dystrophic Epidermolysis Bullosa

* PROQR RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR DRUG CANDIDATE QR-313 FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:

BRIEF-Proqr reports loss of EUR 0.42 per share​

* Proqr Therapeutics Nv - net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share Source text for Eikon: Further company coverage:

BRIEF-ProQR doses first LCA 10 patient in clinical trial of QR-110

* ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness

BRIEF-JDG B.V. reports 10.5 pct passive stake in ProQR Therapeutics NV as on Sept 14

* JDG B.V. Reports 10.5 percent passive stake in ProQR Therapeutics NV as on September 14 - SEC Filing Source text: (http://bit.ly/2yhtqSA) Further company coverage:

BRIEF-ProQR announces positive top-line results from a phase 1b study of QR-010

* ProQR announces positive top-line results from a Phase 1b study of QR-010 in subjects with Cystic Fibrosis

BRIEF-ProQR gets orphan drug designation from FDA for drug candidate QR-313

* ProQR receives orphan drug designation from FDA for drug candidate QR-313 for dystrophic epidermolysis bullosa and will present data at two scientific conferences

BRIEF-ProQR Therapeutics spins out Amylon Therapeutics

* ProQR therapeutics - spun out Amylon Therapeutics, a privately-held company focused on development of therapies for central nervous system disorders

BRIEF-ProQR Q2 loss per share EUR 0.47

* ProQR Therapeutics - enrollment completed in phase 1b clinical trial in cystic fibrosis (CF) and top-line data expected to be announced in September Source text for Eikon: Further company coverage:

BRIEF-Invus Public Equities reports 6 pct passive stake in Proqr Therapeutics

* Invus Public Equities reports a 6 percent passive stake in Proqr Therapeutics NV as of july 3, 2017 - sec filing Source text - http://bit.ly/2sJLPGD Further company coverage:

BRIEF-Proqr to present QR-010 data at European Cystic Fibrosis Society conference

* Proqr to present QR-010 data at the European Cystic Fibrosis Society conference and provides an update on the ongoing phase 1b trial

BRIEF-ProQR reports Q1 loss per share EUR 0.45

* ProQR Therapeutics NV - at March 31, 2017, ProQR held cash and cash equivalents of EUR 52.1 million, compared to EUR 59.2 million at December 31, 2016

BRIEF-ProQR announces clearance of IND application to start QR-110 clinical trial

* ProQR Therapeutics NV - top-line trial results are expected in 2018 from trial

BRIEF-Proqr appoints David Rodman, MD as chief development strategy officer

* ProQR appoints David M. Rodman, MD as chief development strategy officer Source text for Eikon: Further company coverage:

BRIEF-ProQR posts Q4 loss per share EUR 0.38

* ProQR announces results for the fourth quarter and full year 2016 and provides a business update

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up